Clinical Trials Browser

Phase 2 × Ovarian Neoplasms × Carboplatin × Clear all

NCT05952453 2026-03-11

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

Phase 2 Recruiting

Ovarian Neoplasms

NCT07407452 2026-02-12

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT01081951 2026-02-05

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Phase 2 Active not recruiting

162 enrolled 15 charts

Ovarian Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT02001272 2025-12-19

EWOC-1

Phase 2 Completed

Ovarian Neoplasms

NCT07285941 2025-12-16

Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment

Phase 2 Recruiting

Ovarian Neoplasms

NCT06964165 2025-11-26

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Phase 2 Terminated

36 enrolled 11 charts

Ovarian Neoplasms

NCT05456685 2025-10-28

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT03188432 2025-10-21

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

50 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05446870 2025-10-01

MK-4830-002

Phase 2 Completed

160 enrolled 19 charts

Ovarian Neoplasms

NCT04387227 2025-09-18

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Ovarian Neoplasms

NCT05489211 2025-07-11

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2 Recruiting

GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05605535 2025-07-11

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07022535 2025-07-02

PRESELECT-0

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07023484 2025-07-02

Preselect-1

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03783949 2025-06-11

EUDARIO

Phase 2 Completed

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06437353 2024-11-27

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms

NCT02124421 2024-11-19

CRS/HIPEC

Phase 2 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01696032 2024-08-27

SGI-110

Phase 2 Completed

120 enrolled 22 charts

Ovarian Neoplasms

NCT05080556 2024-04-12

ACTOv

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT01001910 2024-02-28

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

22 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02766582 2024-02-26

Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

Phase 2 Completed

29 enrolled 9 charts

Ovarian Neoplasms

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms, Recurrence

NCT01357161 2023-09-21

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Phase 2 Completed

136 enrolled 15 charts

Ovarian Neoplasms

NCT05201001 2023-09-11

APX005M

Phase 2 Withdrawn

Ovarian Neoplasms

NCT00993655 2023-08-28

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Phase 2 Completed

275 enrolled 13 charts

GynecologicThoracic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pleural Effusion, Malignant

NCT03410784 2023-03-24

MITO28MaNGOov4

Phase 2 Unknown

Ovarian Neoplasms

NCT03321188 2023-02-06

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

Phase 2 Unknown

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02125513 2022-12-30

GOGER-01

Phase 2 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01097746 2022-10-28

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Phase 2 Completed

33 enrolled 10 charts

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02562365 2022-07-27

ACTS

Phase 2 Unknown

Ovarian Neoplasms

NCT00432094 2022-05-17

Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

Phase 2 Completed

23 enrolled 11 charts

GenitourinaryGynecologic

Ovarian Germ Cell Cancer, Ovarian Neoplasms, Teratoma, Testicular Neoplasms, Carcinoma, Embryonal, Seminoma, Endodermal Sinus Tumor

NCT02107937 2022-05-04

Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05158062 2022-04-26

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Phase 2 Unknown

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT03029611 2022-01-14

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

Phase 2 Terminated

11 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00945191 2021-04-08

Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer

Phase 2 Completed

24 enrolled 9 charts

Ovarian Neoplasms

NCT02249013 2021-03-18

Short-course HIPEC in Advanced Epithelial Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms

NCT04661696 2020-12-10

Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.

Phase 2 Unknown

Ovarian Neoplasms

NCT00391118 2020-10-19

Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")

Phase 2 Completed

153 enrolled 20 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04590625 2020-10-19

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Phase 2 Unknown

Ovarian Neoplasms

NCT01616303 2020-09-14

A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

Phase 2 Completed

Adenocarcinoma, Neoplasms, Ovarian Neoplasms

NCT00030446 2020-04-08

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01847677 2020-04-01

NOVA

Phase 2 Terminated

Ovarian Neoplasms

NCT00214058 2019-11-19

Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

Phase 2 Completed

Ovarian Neoplasms

NCT01735071 2019-11-19

Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms

NCT01248962 2019-10-02

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

Phase 2 Completed

146 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01739218 2019-08-13

ANTHALYA

Phase 2 Completed

Ovarian Neoplasms

NCT01196429 2019-08-08

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Phase 2 Completed

90 enrolled 10 charts

Ovarian Neoplasms